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Abstract: Spinal cord injury (SCI) can lead to severe motor, sensory and social impairments having
a huge impact on patients’ lives. The complex and time-dependent SCI pathophysiology has been
hampering the development of novel and effective therapies. Current treatment options include
surgical interventions, to stabilize and decompress the spinal cord, and rehabilitative care, without
providing a cure for these patients. Novel therapies have been developed targeting different stages
during trauma. Among them, cell-based therapies hold great potential for tissue regeneration after
injury. Neural stem cells (NSCs), which are multipotent cells with inherent differentiation capabilities
committed to the neuronal lineage, are especially relevant to promote and reestablish the damaged
neuronal spinal tracts. Several studies demonstrate the regenerative effects of NSCs in SCI after
transplantation by providing neurotrophic support and restoring synaptic connectivity. Therefore,
human clinical trials have already been launched to assess safety in SCI patients. Here, we review
NSC-based experimental studies in a SCI context and how are they currently being translated into
human clinical trials.
Keywords: spinal cord injury; cell-based therapies; induced pluripotent stem cells; neural stem cells;
clinical trials
1. An Overview on Spinal Cord Injury
Spinal cord injury (SCI) is one of the most disabling and devastating neurological injuries. It is
recognized as a global health issue priority due to its impact on patient quality of life, complexity,
and expensive medical care (Global Burden of Disease Study 2016 [1]). In 2016, the number of new SCI
cases was 0.93 million (0.78–1.16 million) with a prevalence of 27.04 million (24.98–30.15 million) cases.
Although the global incidence is similar between genders, men have higher incidence when compared
with women at ages 20–40 years. Moreover, as the global population tends to grow and the health care
systems to improve, it is expected an increase in the absolute number of people living with SCI [1].
Upon trauma, SCI patients can be stratified according to the spinal cord level affected, from higher
cervical lesions that lead to partial or full tetraplegia (paralysis of the four limbs) to lower lesions
that lead to paraplegia (paralysis of the lower limbs) [2]. Moreover, SCI etiologies can be subdivided
into non-traumatic and traumatic injury. Non-traumatic SCI occurs when an acute or chronic disease
(such as tumor, infection, or degenerative disc disease) causes the primary injury in the spinal cord,
while traumatic SCI results from an external physical impact sufficient to damage the spinal cord
(for instance, originated by a car crash, falls, violence or sports-related accident). Curiously, it was
estimated that falls are the main cause, accounting for more than 50% of the total incidence [1].
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1.1. From Acute to Chronic Phase
SCI can be described as a two-phase process: an initial acute phase divided in the “primary
injury” and the “secondary injury”; and the chronic phase [3,4]. The “primary injury” depicts the time
when the spinal cord is actually lesioned. Regarding the secondary events, it can occur over the time
course of minutes to weeks, relying on a complex biological cascade of events that may aggravate
the neurological outcomes. Finally, the onset of the chronic phase can occur days to months after the
primary injury and continues throughout the patient’s life. Figure 1 represents the typical biological
events of each phase.
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Figure 1. Underlying biological events during acute and chronic phases after spinal cord injury. The 
primary insult to the spinal cord immediately leads to a cascade of events that comprises the 
“secondary injury”. Weeks to months after the acute phase, the chronic phase is established and it 
may last throughout the patient’s life. 
The pathophysiology behind each phase has been extensively studied allowing us a better 
understanding of the biochemical and cellular events that occur after injury. The initial impact leads 
to immediate hemorrhage and cell death. Then, the “secondary injury” takes place, which was first 
suggested by Dr. Allen, in Philadelphia (1911). In his work, Dr. Allen reported improvements in the 
motor function of lesioned dogs after successfully removing the inflammatory fluid [5]. 
Thenceforth, extensive work has been developed to dissect the potential events that could be 
exacerbating the lesion severity during the acute phase [6]. These include vascular disruption, 
ischemia, edema [7–9], cell death (necrosis and apoptosis) [10], excitotoxicity, ionic imbalance 
[11,12], and a dysfunctional inflammatory response [13–15]. 
During the chronic phase there is dissolution of the grey matter, white matter demyelination, 
deposition of connective tissue, and the formation of the glial scar. In addition to all these 
physiological complications, many SCI patients also experience the development of pain syndromes 
[11] and mood disorders, like depression [16,17]. The glial scar is driven by reactive gliosis of 
astrocytes, microglia/macrophages, pericytes, and extracellular matrix molecules, acting as a 
physical barrier that limits axonal growth [18–21]. Myelin-associated proteins and proteoglycans 
are among the most inhibitory molecules in the central nervous system (CNS). Nogo-A, myelin-
associated glycoprotein (MAG), and the chondroitin sulphate proteoglycans (CSPGs) have been the 
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(MAG), and the chondroitin sulphate proteoglycans (CSPGs) have been the most studied ones [22–24].
Interestingly, several authors have already demonstrated that blocking such inhibitors in a SCI animal
model leads to axonal regeneration and functional recovery [25–27].
Despite the inhibitory environment, after the injury, the spinal cord and the brain tend to
reorganize and establish new circuits in a process called neuronal plasticity. Hollis and coworkers
(2016) demonstrated that after a C5 dorsal column lesion in rats the motor cortex was able to remap when
continuous training was performed. Moreover, when observing SCI patients, significant alterations in
the brain reorganization were shown. In comparison with the control group, SCI patients showed
a reduction in the sensorimotor cortex patterning activation under functional magnetic resonance
imaging (fMRI) [28]. When looking to the spinal cord itself, several studies suggest that physical
activity is one of the most critical influencers in neuronal plasticity. Regarding human studies, physical
therapy is currently applied to incomplete SCI patients with positive results in patients’ recovery.
Overall, SCI is a multi-dynamic process with no effective treatment mainly due to the failure of
the CNS to successfully regenerate the damaged neuronal circuits. Therefore, researchers have been
exploring novel therapies that can be translated into clinical meaningful recovery.
1.2. Clinical Management After SCI
Despite the major efforts currently made to develop new therapies for SCI, there is still no effective
treatment. Numerous studies have reported some positive results in preclinical SCI models, however,
translation to patients is still questionable and controversial. Typically, after trauma, the patient
is completely immobilized and is constantly monitored to prevent possible complications, such as
respiratory dysfunctions, cardiovascular aberrations, and hypoxia [29]. After stabilization, clinicians
surgically decompress the spinal cord and control the lesion site [30].
The anti-inflammatory methylprednisolone sodium succinate (MPSS) was the first-line drug
treatment for SCI patients [31]. Now spanning 50 years, a cordial discussion remains open regarding
MPSS administration, safety, dosage, and time-administration [32,33]. Although neuroprotective effects
were observed in preclinical studies as well as neurological improvements after its administration,
the heightened risks of infection and death are a real concern for patients under MPSS treatment.
In fact, the most recent guidelines from the Congress of Neurological Surgeons/American Association
of Neurological Surgeons discouraged the administration of MPSS in acute SCI. Therefore, MPSS is
not a viable long-term therapeutic choice, highlighting the need to develop new treatments targeting
specific events that occur during the acute and/ or the chronic phase.
1.3. Novel Treatments for SCI
Pharmacologically, new neuroprotective alternatives have been targeting secondary events such
as inflammation and excitotoxicity. Among them, minocycline and riluzole are two examples that
are already under clinical trials. Minocycline, a semisynthetic tetracycline antibiotic, is classified as
a neuroprotective agent by improving the exacerbated inflammatory microenvironment observed
during secondary SCI [34]. After positive motor outcomes observed during phase I/II clinical trial,
the pharmacological administration of minocycline was further encouraged to be tested in a phase
III clinical trial (Minocycline in Acute Spinal Cord Injury (MASC)—NCT01828203) [35]. Riluzole,
a benzothiazole anticonvulsant, showed to be able to block the abnormal glutamatergic transmission
in neuronal synapses [36]. Preclinical studies strongly pointed out for a beneficial effect in neurological
tissue preservation and motor recovery [37,38]. Consequently, and after the positive effects reported
during the phase I/IIa clinical trial, riluzole is now involved in an international phase II/III multi-center
clinical trial (Riluzole in Acute Spinal Cord Injury Study (RISCIS)—NCT01597518) [39,40].
Fibroblast growth factor-2 (FGF-2; or basic fibroblast growth factor) has been implied in different
biological processes, such as limb and nervous system development, wound healing, and tumor
growth, due to its function in cell proliferation and survival [41]. Regarding SCI, different reports have
evidenced a role for FGF-2 in spinal cord neural stem and progenitor cells proliferation, angiogenesis,
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and glial cavitation reduction. While some SCI animal models shown hind limb improvements
after intrathecal injection of FGF-2, other studies do not report any functional recovery benefits after
treatment. Still, a human clinical trial is now being conducted to assess safety and efficacy of a specific
biodegradable device with heparin-activated FGF1 in traumatic SCI patients (NCT02490501). The aim
of the study is to develop a regenerative treatment option by taking advantage of the crucial role of
FGF1 in neuroprotection and axon regeneration of the CNS [41,42].
Cytokines also exhibit interesting characteristics that can promote morphological and functional
recovery of the spinal cord after trauma. The most widely studied cytokine for SCI treatment is the
Glycoprotein Granulocyte Colony-Stimulating Factor (G-CSF), known to reduce inflammatory cytokine
expression and to promote survival of ischemic cells [43]. Moreover, in a nonrandomized phase I/IIa
clinical trial the administration of G-CSF demonstrated to be safe, leading to some improvements in
the American Spinal Cord Injury Association (ASIA) scale [44,45]. Another promising cytokine for
SCI treatment is interleukin-4 (IL-4). This cytokine is able to activate macrophages to a phenotype
associated with repair [46]. Preclinical studies have demonstrated neuroprotection and motor recovery
after the administration of IL-4 [47,48].
Besides these molecular approaches, stem cell-based therapies have shown great potential over
the past decades, based on the rationale that transplanted cells can differentiate and substitute the lost
tissue. Moreover, stem cell-based treatments can also modify the microenvironment and regenerate the
damaged circuits. However, there are also some challenges inherent to cell transplantation, including:
the choice of the cellular source, the establishment of differentiation protocols, and the monitoring of
cell grafts survival and integration.
Regarding stem cell transplantation, encouraging results have already been reported for spinal
cord repair, being particularly relevant for neuronal and glial replacement, remyelination, connectivity
restoration, stimulation of precursor cells, as a bridge of cysts/cavities, and for improving the expression
of beneficial neurotrophins/cytokines. A wide plethora of different cell-types has already been tested
and transplanted into the injured spinal cord, both in animals and humans, including Schwann cells [49],
olfactory ensheathing glia [50], skin-derived precursors [51], mesenchymal stem cells (MSCs) [52],
oligodendrocyte progenitor cells (OPCs) [53], and neural stem/progenitor cells (NS/PCs) [54]. Although
all cell-types have intrinsic advantages but also limitations, the focus of the present review is directed
for NSC-based therapies.
2. Stem Cells in SCI: Past, Present, and Future
2.1. From the Embryo to A Structured Spinal Cord
The human embryonic development of the nervous system is a complex and highly tuned-process.
During the embryonic period, the primary three germ layers (ectoderm, mesoderm, and endoderm)
are established as the basis of the various systems and organs of the body through numerous mitotic
divisions. As illustrated in Figure 2, from a solid mass of totipotent cells—morula—the embryo
develops into the blastocyst. The blastocyst is a pluripotent structure that consists of a cellular outer
layer of trophoblasts and an inner Embryonic Stem Cell (ESC) population, the inner cell mass (ICM) [55].
From the ICM cells adjacent to the cavity, a new layer of flat cells is formed, the hypoblast, while the
rest of them remain relatively undifferentiated and are termed as epiblast. Subsequently, the blastocyst
becomes attached to the endometrium of the uterus, and epiblast cells migrate ventrally along the
median plane to form the primitive streak. Embryonic cells begin to differentiate, replacing the
hypoblast by the endoderm whereas the remaining part of the epiblast arises to the ectoderm [56].
This process is termed as gastrulation where the monolayered blastula forms a bilayer gastrula with
the well-defined primary layers. It is from the ectoderm the notochordal process began, that which
will ultimately will arise into the nervous system [57,58].
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Figure 2. Embryonic development and cellular differentiation. After fecundation, the entire embryogenesis
is spatially and temporally coordinated dynamically shifting the gene expression, cell growth, and
cellular differentiation.
At approximately the 23rd day of development, the neural plate is already observed in the embryo
initiating the neurulation process. As the neural plate begins to roll-up, it develops into the neural
tube and consequently to the neural crest [58]. During this period, ESC-derived epiblast-like cells
are redefined as neuromesodermal progenitors (NMPs) and are the cellular source for spinal cord
development [59,60]. Timed and spatial expression pattern of TBX6 and SOX2 genes in NMPs drive
cells into their mesoderm or neural fate [61]. Further, other specific patterning genes regulate the
neural subtype fate of neural stem cells (NSCs) along the rostral-caudal and dorsoventral axis, in a
concentration-dependent manner. While retinoic acid (RA) is highly involved in the activation of rostral
homeobox (HOX) genes (HOX1-5 paralog) responsible for a more broad brainstem-to-rostral cervical
spinal cord identity, the balance between WNT and FGF signals induces a more caudal neuroaxis
spinal HOX gene expression (HOX6-9 paralog), specifically for a cervical and thoracic spinal cord
identity [62–64]. Once the neurulation process is concluded, cells begin to differentiate into mature
neurons, being the motor neurons the first ones to develop. Architectonic organization of the spinal
cord becomes more and more complex and neurons, non-neurons, and fibers become myelinated for the
development of the major tracts of the spinal cord. Fully maturated, the spinal cord is composed by the
white matter (mostly myelinated axons) surrounding the gray matter (mostly interneurons, cell bodies,
and glial cells). In the white matter the axons are organized in fiber tracts that run longitudinally
through the spinal cord, ascending tracts transmit information from the periphery to the CNS and the
descending tracts relay information from the brain to the rest of the body.
2.2. Historical Perspective of Cell-Based Research
Over the pa t decades, we have b en witnessing to unprecedented and groundbreaking progress
in cell-based research (Figure 3). The potential of such tools has been capturing the attention of
the scientific community, clinicians, as well as the general public. The idea of innovative cell-based
therapies to treat a wide spectrum of human diseases and traumas has been inspiring researchers.
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2.2.1. Finding Embryonic Stem Cells
Cell-based research turning point begun in the 20th-century when Stevens and Little (1954) were
deciphering the complexity of teratocarcinomas. These tumors contained a relatively undifferentiated
cell-type known as “Embryonal Carcinoma Cells” (ECCs), long suspected as the stem cell of the
tumor [65]. In the following decade, an emerging interest regarding ECCs was notorious, culminating
in some important findings, namely: (1) a si gle tumor-derived cell is able to differentiate into all the
heterogeneous cell types that are typically found in a teratocarcino a [66]; (2) ECCs can be continuously
expanded in vitro when co-cultured with inactivated mouse embryonic fibroblasts (MEFs); (3) after
blastocyst ECC injection a chimeric mouse can be generated [67,68]; and (4) differentiation into any
embryoni germ layer [69,70].
The ECCs therapeutic potential was compromised due to their tumorigenic potential and
aneuploidy karyotype. In an attempt to overcome this drawback, in 1981 two independent laboratories
reported the isolation and establishment of ESCs from early mouse embryos [71,72]. By resorting to
pre-implanted blastocysts, Evans, Kaufman, and Martin surgically removed the ICM, a sharp source
of pluripotent cells, and culture it on fresh feeder layers under conditioned medium. As a result,
they obtained a normal diploid ESC line that could differentiate into all mature cell-types from the
three germ layers in vitro, and in vivo [71,72]. In 1984, Andrews et al. and Thompson et al. resorted
to Tera-2, the oldest extant cell line established from a human teratocarcinoma, to isolate and derive
genetically identical clone cells. They observed that clones were highly adapted to culture overgrowth
and could maintain their differentiation potential. Moreover, under retinoic acid exposure, clones were
capable of differentiating into neuron-like cells and other somatic cell-types [71–73]. As the knowledge
regarding pluripotency mechanisms improved, the derivation and differentiation protocols began to
be more refined. For instance, Matsui et al. (1992) enhanced the long-term culture of ESCs by adding
bFGF to the culture medium [74].
Considering the advances in animal derived-ESCs, the isolation and culture of human pluripotent
cells became an exciting challenge at the time. In 1993, Bongso et al. described for the first time
the development and maintenance of ICM cultures and the following isolation of ES-like cells from
its center. Cells maintained a normal karyotype and stemness-like morphology, however, a limited
number of clusters differentiated into fibroblasts [75]. In 1998, two groundbreaking works were
reported the establishment of embryonic germ cell (EGC) and ESC lines isolation from a human
source [76,77]. Shamblott et al. reported the isolation of PGCs from gonadal ridges and mesenteries
at 5–9 weeks post-fertilization, which after a period of 7–21 culture days were positive for alkaline
phosphatase activity and also for a commonly panel of immunological markers (SSEA-1, SSEA-3,
SSEA-4, TRA-1–60, and TRA-1–81) used to characterize ESCs and EGCs [76]. Later, Thomson and
his co-workers announced the derivation and establishment of ESCs in non-human primates. After
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several passages, the cells retained a normal karyotype, high levels of telomerase activity and typical
pluripotency markers expression [77]. To obtain ESCs, researches were using blastocyst which is
an embryonic structure that derives after fecundation which implies the use of human embryos.
As expected, this idea started to provoke some discussion in the media due to the ethical and religious
concerns involved. Despite the controversy, in the following years, different groups developed
several ESC lines improving in vitro culture approaches and differentiation protocols. Traditionally,
MEF feeders were used to support ESCs growth, however, the relevance of ESCs for a therapeutic
approach motivate the reassessment of these support systems, considering the high risk of pathogens
cross-transference from the animal feeder cells. A novel xeno-free system was suggested by Richards
et al., (2002) with all animal-based products discarded, empowering the potential application of ESCs
into the clinic [78].
Therefore, the first clinical trial using human ESC-derived OPCs was approved in 2010
(NCT01217008) [79,80]. The cells were transplanted into patients with spinal cord injury (SCI)
and no major complications were reported regarding toxicity, allodynia, or tumor formation [81].
A phase I/IIa dose-escalation study was then initiated in 2014 (NCT02302157), and considering the
updates from the responsible biotech company, OPCs were successfully engrafted into the spinal cord
of patients. Moreover, some motor improvements were observed, but the official data for the entire
study is expected to be published in the first quarter of 2019.
In conclusion, some convergent points stood out and common ESCs characteristics were established
among the scientific community: (1) source of pluripotent cell population; (2) maintenance of a stable
and diploid karyotype; (3) indefinite propagation in a primary embryonic state; (4) differentiation
into any mature cell-type of the three embryonic germ layers; and (5) expression of specific nuclear
and cytoplasmic markers of pluripotency [82]. All these characteristics put ESCs forward as good
candidates for a wide range of applications, including as a platform for organogenesis studies through
the generation of complex tissues such as, the patterned neural tube [83], cerebral organoids [84], and a
mature spinal cord [85].
2.2.2. Searching for Pluripotency in Adult Tissues
Despite the excitement created around the ESCs therapeutic potential some issues were hampering
their translation to the clinics, mainly, ethical concerns, tumorigenic potential, and impossibility for
autologous transplantation. Adult stem cells, such as mesenchymal stem cells, were a viable alternative,
however, their differentiation potential is limited. Thus, further efforts were pursued to find a source
of pluripotent stem cells (PSCs).
Unexpectedly, in 1962 Gurdon et al. reported the full development of a complete Xenopus organism
by transferring the nucleus from a somatic cell to an enucleated egg [86]. Although in a very primitive
way, Gurdon et al. explored for the first time the concept of reprogramming somatic cells into
pluripotent cells. These developments paved the fundamentals of somatic cell nuclear transfer (SCNT)
technique which allows the production of genetically suitable cells and tissues. Particularly, it was
through SCNT that the famous “Dolly the sheep” was produced, a live offspring capable to mature
into adulthood [87]. Despite the notable progress in SCNT research, human experiments were still
intolerable due to the ethical concerns [88].
Therefore, additional methodologies were explored to generate PSCs such as: parthenogenesis [89],
cell fusion [90], direct somatic cell reprogramming [91], and testis-derivation [92], (see the Muller
and Lengerke (2009) review [93]). Among all, when pros and cons are balanced direct somatic cell
reprogramming shows to be the most promising technique opening up unprecedented opportunities
for regenerative medicine. The groundbreaking report was originally published by Takahashi and
Yamanaka in 2006 where they remarkably demonstrated the generation of induced PSCs (iPSCs)
from mouse skin fibroblasts. After a full genomic screening, Takahashi and Yamanaka filtered 4
out of 24 genes as pivotal transcriptional factors for the induction and maintenance of iPSCs in an
ES-like state: Oct3/4, Sox2, c-Myc, and Klf4 (Figure 4). As a proof of concept, the particular features
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of ESCs were also present in iPSCs, namely: (1) resembling morphology and growth properties;
(2) expression of specific gene markers; (3) tumor formation after transplantation in nude mice;
(4) tissue differentiation from all the primary germ layers in the tumor; and (5) complete embryonic
development after mouse blastocysts injection [91]. Overall, Takahashi, and Yamanaka created
important foundations in regenerative medicine by producing autologous cells and thus, avoiding the
need for immunosuppressive agents after transplantation. This pioneering work was the base for the
recognition in 2012 with the Nobel Prize in Physiology or Medicine award for Shinya Yamanaka.
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KLF4, c-MYC) to induced pluripotent stem cells (iPSCs). Induced PSCs can further be used as a novel
therapeutic strategy for cell transplantation.
Despite all the benefits, there are some inherent limitations of iPSCs that must be kept in mind to
ensure safety (Table 1), such as the potential risk of inducing genomic and/or epigenomic alterations
during iPSCs reprogramming [94,95]. Nevertheless, over the past years, rapid and extensive research
has been done to improve iPSCs technology to be applied in regenerative medicine, drug therapy, and
disease modeling [96].
Table 1. Overview of the advantages and limitations of induced pluripotent stem cells generation and
est lishment from s matic cells.
Advantages Limitations
No ethical concerns Risk of tumor formation
Evidence on a pluripotent profile (ES-like cells) Epigenetic and genetic alterations
Highly flexible technique Oncogenes reactivation
Derivation from any somatic cell Expensive and time-consuming
Patient-specific source (no immune rejection)
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The generation of iPSCs have already been done from a wide range of tissues, from adult human
fibroblasts [91,97] to liver and stomach [98,99]. In 2007, Yu et al. modified the gene set used by
Takahashi and Yamanaka and instead of the tumorigenic c-MYC, the authors used Lin-28 obtaining a
similar population of iPSCs [100]. Moreover, Nakagawa et al. (2008) observed that supplementation
with c-Myc was not crucial for iPSCs induction and although the authors reported a significantly lower
reprogramming efficiency, they reduced down to zero the probability of teratoma formation after
transplantation [101].
On the contrary to ESCs, the use of iPSCs as a valuable source for cell transplantation was
well accepted mainly due to the absence of ethical concerns. However, iPSCs also underwent some
challenges; namely by the inappropriate use of animal-derived components and the use of retroviral
vectors to transfect somatic cells. Thus, novel integration-free methods and xeno-free cultures were
developed as well as innovative virus-free strategies [102,103]. These latter advances prompted
exponentially the therapeutic applicability of iPSCs by decreasing the risk of tumorigenicity associated
with viral genomic-integration.
In 2014, Dr. Takahashi and his team (RIKEN, Kobe, Japan) submitted the first-in-human trial using
iPSCs (funded by Highway Program for Realization of Regenerative Medicine and others; University
Hospital Medical Information Network Clinical Trials Registry [UMIN-CTR] no. UMIN000011929).
A patient with neovascular age-related macular degeneration (AMD), a degenerative retinal disease,
received a transplant of a sheet of retinal pigment epithelial (RPE). The RPE cells were differentiated
using autologous iPSCs from skin fibroblasts and no immunosuppressive agents were administrated to
the patient. After transplantation, neither signs of immune rejection were observed nor aberrant genomic
alterations, suggesting no tumorigenesis of the cell graft [104]. These positive outcomes highlight
all the potentialities behind iPSC technology as a novel tool for cellular therapy and have launched
the beginning of more clinical trials targeting many other conditions (see the Kavyasudha et al., 2018
review [105]).
Human iPSCs are mainly obtained from skin fibroblasts however, a skin biopsy may not be the
best source due to the risk of infection and scar formation [97,106]. Thus, other less invasive somatic
cell sources have been considered, such as peripheral blood due to the minimal procedures necessary
to collect it. In fact, clinicians and researchers have strong expectations in peripheral blood as a gold
standard clinical-grade source of iPSCs for the future [80,107].
Additionally, iPSCs technology has also been explored for disease modelling. The establishment of
some disease-specific iPSCs lines have already allowed a better understanding of the mechanisms that
trigger and are behind certain diseases [108]. The first successful report was based on the generation
of iPSCs from a child with Spinal Muscular Atrophy (SMA) [109]. Studies on drug screening and
validation have also been conducted using patient-specific cell lines, and relevant advances have
already been achieved, for instance, in Rett syndrome [110], and in Fanconi anemia [111].
In conclusion, iPSCs represent a very flexible technology that opened new and challenging
opportunities to develop cell-based therapies due to its ability to differentiated into any cell-type
given the right culture conditions. The numerous advantages of induced stem cells, from no immune
rejection to high reproducibility, prompted the field to employ them in patient-specific diseases studies,
developmental studies, cell transplantation as well as in drug screening. As a consequence, we are
now moving fast towards a more personalized medicine.
2.2.3. Neural Stem Cells
In the past, researchers assumed that neurons were only generated during embryogenesis,
however, Altman and Das (1964) published a remarkable report describing the generation of new
neurons in the hippocampal dentate gyrus of an adult rat brain [112]. The generation of new neurons
from NSCs is a highly tuned process during nervous system development. Nevertheless, neurogenesis
also occurs throughout adult life as an extremely limited process that attempts to sustain a proper
balance between self-renewal and differentiation [113,114]. In the adult brain, the two best described
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niches that harbor NSCs are the subventricular zone (SVZ) and the periventricular region of the spinal
cord [113,115].
Therefore, the idea of transplanting NSCs is a very promising therapeutic approach for many
neurodevelopmental, neurodegenerative, and neurotraumatic diseases by replacing and reestablishing
damaged neuronal circuities [114]. Thus, one of the first topics that should be discussed is how
would NSCs be obtained taking in consideration both the cell source and the cell dosage required
for adequate transplantation. Until this point, there are three main sources: direct isolation from
primary CNS tissue (either from the fetal or adult brain); differentiation from pluripotent stem cells;
and, transdifferentiation from somatic cells (Figure 5).
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Figure 5. Neural stem cell (NSCs) sources and their therapeutic applicability after cell transplantation.
There are three main sources to generate NSCs: isolation from primary central nervous system (CNS)
tissue; differentiation of pluripotent stem cells, and lineage reprogramming of somatic cells. After
obtaining a considerable number of cells that fulfill the needs of cell transplantation cells can be applied.
Once on the injury site, NSCs can be differentiated and also secrete paracrine factors that may also
support neurological repair.
NSCs from CNS primary tissues. In 1992, Reynolds and Weiss were the first to report the isolation
and culture of NSCs in spherical clusters (neurospheres) from the striatal neurogenic area of an adult
mouse brain [116]. Two years later, they remarkably demonstrated in vivo that the subependymal
region is a viable source of NSCs in the mouse brain [117]. Concomitantly with their work, two specific
mitogenic growth factors, the epidermal growth factor (EGF) and the bFGF were identified as
critical factors that cooperatively induce self-renewal, proliferation, and expansion of NSCs in clonal
aggregates [115,116]. Indeed, after isolation, NSCs can grow into single-cell suspensions that ultimately
form regular neurospheres. These non-adherent neurospheres are particularly interesting due to their
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self-renewal capacity and because of their capability of establishing a favorable extracellular-matrix
microenvironment that helps to maintain stemness. Moreover, neurospheres can be sub-cultured and
expanded to increase the available pool of cells. Adult NSCs have, however, the disadvantage of not
being able to be used as an autologous cell source.
Differentiation of NSCs from pluripotent stem cells. PSCs have been used as a very attractive
alternative to primary tissue isolation. Differentiation of NSCs from ESCs and iPSCs gained a lot of
attention due to their therapeutic applicability potential. As previously discussed, iPSC-derived NSCs
have striking advantages over ESC-derived NSCs, namely the possibility of autologous transplantation.
Regarding differentiation protocols, PSCs have been cultured either as embryoid bodies (EB) or
in monolayer cultures. Considering EBs, they grow in suspension and can be differentiated into
neural tube-like rosettes and, subsequently, into NPCs under specific conditions [118]. More recently,
differentiation protocols of NSCs using iPSC-derived EBs have also been standardized and applied
as a promising alternative for cell transplantation [119,120]. Additionally, NSCs can be generated
in monolayer cultures using serum-free specific inhibitors and growth factors that contribute to
neuronal specification [121,122]. Overall, when comparing both techniques there are no major
differences on the typical expression markers of NSCs and morphology. Nevertheless, there are
some drawbacks associated with both assays. The EBs are 3-dimensional (3-D) spheroids structures
capable of spontaneous differentiation mimicking better the embryonic development by promoting a
heterogeneous differentiation, which is also a synonym of low reproducibility of the technique [123,124].
On the other hand, monolayer cultures need continuous passaging to maintain self-renewal and cell
potency. 2-D attachment also interferes with the shape and geometry of colonies, which might be
deleterious for internal cytoskeleton shape [125,126].
Transdifferentiation of NSCs from somatic cells. Transdifferentiation is the differentiation of cells
to a certain cell-type that does not follow the “normal” programmed differentiation mechanism [127].
This term was first applied by Selman and Kafatos (1974) and it is characterized by a direct
reprogramming or conversion of one mature somatic cell type into another cell type without undergoing
an intermediate pluripotent state [128]. Lineage reprogramming is mainly induced by the expression of
endogenous lineage-specific transcription factors (TFs) [129] and by specific chemical compounds [130].
Yao et al. (2015) produced transdifferentiated induced NSCs (iNSCs) after conditionally overexpressing
specific TFs (Oct4, Sox2, Klf4, c-Myc) from mouse embryonic fibroblasts. The transdifferentiated
cells differentiated into mature astrocytes, neurons, and oligodendrocytes in vitro, and after being
transplanted into a stroke rat model, they were able to reduce the lesion size and promote the
recovery of motor and sensory function [131]. The TF-induced transdifferentiation has inherent
issues associated with the use of exogenous viruses, so, chemical compounds [132] and growth
factor-induced transdifferentiation [133] have been developed ensuring advantages in terms of safety.
Transdifferentiation has become a powerful tool to study how cells might be manipulated for specific
therapeutic purposes [134]. Nevertheless, this field is very recent and further investigation is still
needed before the development of personalized regenerative therapies.
2.3. Advances on NSC-based Therapy for SCI
In 1999, McDonald et al. were the first to demonstrate the potentialities of NPCs transplantation
in a SCI context. After deriving neural progenitors from mouse ESCs (mESCs) and transplanting them
into a rat spinal cord 9 days post-injury they observed that grafts had the capacity to survive and
differentiate into neurons, oligodendrocytes, and astrocytes, and to migrate along the rostro-caudal
axis from the lesion epicenter. More importantly, the transplanted experimental group showed hind
limb weight support and partial walk coordination [135]. From then on, numerous studies have
been deciphering the mechanisms behind NSCs effects on SCI. However, there are still some critical
questions that remain to be answered and should be addressed, such as, the optimal time-window of
efficacy, the number of transplanted cells, the cellular source, safety, and administration routes.
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After grafting mouse fetal striatal NS/PCs 12 wpi into a contusion T10 mice model, Kumamaru et al.
(2013) observed that cells were capable of releasing multiple regenerative molecules and to differentiate
into neurons/oligodendrocytes contributing for a neurogenic spinal cord environment, however, no
locomotor improvements were observed [136]. Efforts were also done by Cheng et al. (2017) to explore
the appropriate timing for NSCs administration. After injecting hNSCs in a contusion T10 SCI model 1
or 4 wpi, both groups showed significant functional improvement at the motor level, but the effect
was more prominent in the acute 1 wpi group [137]. Using NOD/SCID mice, after a T9 injury model,
hCNS-derived NSCs were immediately injected after the inflicted injury and no locomotor recovery
was observed [138], on the other hand, when Salazar et al. (2010) only applied the cells 4 wpi mice
displayed locomotor improvements [139]. Despite the disparities, cells differentiate into all the three
CNS lineages, survived, and migrated within the injured spinal cord suggesting that hCNS-derived
NSCs transplantation can be effective depending on the time-window of intervention.
Injecting the cells in an earlier phase might be more beneficial to restore the damaged neural
circuits before the formation of the glial scar barrier. Nevertheless, the current number of chronic
patients is highly considerable which should also stimulate the field to get novel strategies and boost
cell transplantation effects in a more chronic phase. Yet, more preclinical studies are needed to better
understand the best time window of NSCs transplantation. As mention above, SCI is a two-phase
injury process with multiphasic cellular and molecular responses that varies along time which makes
it difficult to find the best time-window of treatment [133]. To tackle such oscillations with cell
transplantation between acute and chronic SCI, different protocols must be designed. For instance,
in the acute phase NSCs may need to be transplanted together with some neuroprotective drug because
several biological events are happening in this phase that may hamper cell survival. On the other hand,
NSCs transplanted in the chronic phase may need the help of drugs that degrade the glial scar in order
to better integrate in the host tissue.
The cellular source to obtain NSCs is also an important variable to be considered. First, animal
studies must be carried out to better comprehend and explore the cellular viability and to decipher
some potential targets of NSCs after transplantation. Further, preclinical studies are mandatory
before conducting a clinical trial mainly to assess safety. Fetal brain and spinal cord are the two
main sources used to generate viable NSCs. Using mouse fetal cortex, Cheng et al. (2016) injected
NSCs in an acute contusion SCI mice 7 dpi and observed a reduction in M1 macrophages activation,
neutrophils and iNOS+/Mac-2+ cells at the epicenter of the injured area. Although the underlying
factors remain unknown, this beneficial anti-inflammatory profile was translated into a significantly
enhanced neurological function in mice [140]. Additionally, different studies have also reported some
locomotor improvements after chronic transplantation of NSCs using different cellular backgrounds
from the mouse striatum [141], to shrew fetal hippocampus [142], to the rat fetal brain [143].
Concerning human fetal spinal cord NSCs, positive results have also been reported regarding
axonal growth at the injured site. For instance, Kadoya et al., showed that after transplantation there is
an extensive regeneration of the corticospinal axons, improving synaptic connectivity and forelimb
functioning [144]. Meanwhile, Robinson et al. (2017) added to E14 spinal cord-derived NPCs a 4-factor
cocktail (BDNF, bFGF, VEGF, MDL) which promoted significant maintenance of grafts survival and
neural differentiation, fulfilling the lesion site [145].
The capacity of pluripotent mESCs to differentiate into the neural lineage has also been explored
to reestablish the damaged circuits after a SCI. In a contusive SCI model, NSCs derived from a mESC
line J1 were intrathecally transplanted 3 wpi showing the ability to differentiate into spinal GABAergic
neurons and to attenuate chronic neuropathic pain [146]. In a moderate compression injury of the
spinal cord, Salewski et al. (2015) performed acute transplantation of mESC-derived NSCs and the
treated group showed significant functional improvements 8 wpi. During the differentiation protocol
used, the group described an intermediate step of LIF-dependent neurospheres formation, named as
primitive NSCs (pNSCs). Interestingly, they transplanted pNSCs to assess tumorigenic potential which
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resulted in teratoma formation, raising the warning for tumor formation potential of mESC-derived
NSCs as a real safety concern that must be explored during differentiation protocols [53].
Furthermore, preclinical studies have been conducted, approaching different cell sources, to better
comprehend better the cellular response after transplantation namely immune rejection, tumor risk
formation, and grafts survival. Using a human primary source of neural precursors from the fetal
spinal cord (SPC-01) it was showed strong immunomodulatory properties through astroglial p65
NF-κB inhibition which significantly impacted the reduction of the glial scar and the cavity size [147].
Moreover, the well-defined human H9 ESC-derived NSC line has also been commonly addressed
as a cellular source with high reproducibility. These cells are characterized by the expression of
NSC-specific markers, Nestin and SOX2, and the ability to differentiate into neurons, oligodendrocytes,
and astrocytes [148]. After its transplantation to immunodeficient rats, the grafts showed signs of a
continuous maturation over a follow-up of 1.5 years. After 3 months, mature neuronal markers were the
first to be expressed, 6 months later mature astrocytes showed up, and only 1 year after transplantation
mature oligodendrocytes were detected. NSC-derived astrocytes migrated longer-distances in the lesion
site when compared with other cell-types and synergistically engrafted with host astrocytes resulting
in modest improvements in forelimb motor function without any critical adverse outcomes [149,150].
On the other hand, human pluripotent cells have been yielding in the generation and maintenance
of NSCs. Kumamaru and coworkers demonstrated that under specific cues human ESCs (hESCs) can
be derived into NSCs committed to the spinal cord improving the potential of neural cells to restore
the damaged circuities. After transplantation, cellular grafts revealed to be enriched in excitatory
neurons, promoting a robust corticospinal regeneration, engraftment within the host increased synaptic
formation, which has culminated in hind-limb improvements [151].
The discovery of iPSCs was one of the most remarkable innovations in regenerative medicine and
biological research. The concept of convert adult somatic cells, such as blood cells or skin fibroblasts,
into NSCs through iPSCs incited numerous studies in the field. Promising results have been observed
after iPSC-derived NSC transplantation into SCI animal models, promoting cell survival, tissue
preservation, and neuronal differentiation of cells. Moreover, functional recovery was also observed
through the remyelination of axons and upregulation of supportive neurotrophic factors in the spinal
cord [53,152,153].
Summing up, animal studies have been very useful to evaluate and decipher novel mechanistic
insights after cell transplantation, yet preclinical studies are essential to target critical questions as
immune rejection and tumor formation. To circumvent ethical issues and immunosuppression, iPSCs
are now the most attractive human cell source, but further studies are required to ensure efficacy,
feasibility and safety.
After getting a valid cellular source other questions need to be addressed, namely, the following
question raised is, how many cells are needed for a positive outcome? The optimal number of
transplanted cells is still very debatable and few studies have been in order to elucidate the field.
Yousefifard et al. (2016) have recently performed recently a systemic and meta-analysis to tackle some
of these questions regarding NS/PCs transplantation. They reported that the median number of the
cells per kilograms of animal’s body weight was 4.3106 (interquartile range = 1.1106–2107), but the
higher the number of transplanted cells the better was the functional recovery [154,155]. This might be
related with a higher chance of cellular survival, and in addition, it was also observed that the number
of transplanted cells improves hyperalgesia in the animals [155]. Therefore, it would be important to
further study the optimal range of transplanted cells in order to facilitated the translation to humans.
The tumorigenicity risk associated with NSCs transplantation is also a real concern that must be
addressed to ensure patients’ safety. While some studies do not report any tumor formation [139,156]
others documented tumorigenic risk mainly associated with pluripotent-derived NSCs [157,158].
Moreover, as the field advances, evidence has been accumulating on iPSC-derived NSCs tumorigenicity
that must be addressed to ensure high clinical quality in the application of these strategies. There are two
main forms of tumorigenicity, teratomas and true tumors formation [159], yet the mechanisms triggered
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behind each of them are not fully understood. Some studies reported the use of tumor-inducing
reprogramming factors and some residual undifferentiated cells as the main causes that induce
epigenetic alterations in iPSC-derived NSCs [93,94].
Teratomas development is mainly associated with an existent “epigenetic memory” and the lack of
purification in the cellular sample used for transplantation [93]. Some strategies that can be undertaken
are: increasing the number of passages to dissolve the “epigenetic memory”; develop purification
systems with higher yield; reprogram iPSCs to drive away from the teratoma-inducing lineage; or even
transplant cells in a more differentiated state.
To avoid tumor formation during iPSCs reprogramming and differentiation there are some
critical steps that must be carefully performed to avoid epigenetic and genomic instability in
colonies [94]. The choice of the reprogramming method is a key-step to avoid genome disturbance
by choosing integration-free systems over integrative vectors [101,102]. Further, the selection of the
reprogramming factors is also critical, since c-Myc from Yamanaka’s factors is by itself sufficient
to induce tumorigenesis [90,100]. However, it was already showed that c-Myc is not indispensable
for iPSCs generation, avoiding its application [99,100,160]. Recently, based on these withdraws,
Kojima et al. (2018) introduced a specific gene into a tumorigenic human iPSC-NSCs line to successfully
ablate immature proliferating cells, and after transplantation, animals did not develop any tumor,
moreover, this cells promoted motor recovery [156].
The route of administration is also an important topic that must be considered when addressing cell
transplantation. Three main injection routes have been tested to be applied in SCI context: intraspinal,
intrathecal, and intravenous. Amemori et al. (2015) studied different administration routes in an acute
SCI model. NSCs were either injected intraspinally into the lesion center or intrathecally into the
subarachnoid space of rats with compression lesion. Both treatments facilitated functional locomotor
recovery, yet the intraspinal implantation had a higher positive effect in gray and white matter sparing
and axonal sprouting, and reduced astrogliosis when compared to the intrathecal injection [152].
Nevertheless, when Cheng et al. (2012) injected hNSCs both locally at the injury site or distally no
significant differences were observed in functional behavior [161].
Intraspinal injections are the most commonly used route by researchers, however, it is important to
have in consideration some positive results published regarding intravenous administration [162,163].
Nishimura’s et al. (2013) reported that after hNSC intravenous administration animals showed
behavioral improvements, electrophysiological recovery, suppression of glial scar formation, and
preservation of nerve fibers. These results suggest that cells are able to survive, proliferate, and migrate
into the lesion site [163]. Moreover, Osaka et al. (2010) also support intravenous administration of cells
as a minimally invasive approach with high therapeutic potential [164]. Once again, more investigation
should be performed considering the ideal route of administration. Minimal invasive administration
procedures avoid surgical complications to patients, however, we may also lose some therapeutic
efficacy. All these factors should be well studied in the preclinical set up.
On Table 2 it is represented selected preclinical studies employing NSCs for SCI repair. Overall, from a
morphological point of view, NSCs are able to differentiate into neurons, astrocytes, and oligodendrocytes
promoting axonal regrowth, remyelination and regeneration of the CST [145,150,165]. In addition,
NSCs grafts showed consistently the capacity of filling the lesion cavity, reducing the glial scar and
a high chance of survive after transplantation [144,166]. Physiologically, Kumamaru et al. (2018)
showed that differentiated cells from NSCs form new synapses within the host spinal cord below
the lesion. After assessing cell grafts, they also observed that cells present mainly an excitatory
neuronal fate which promotes the host-to-graft connectivity [151]. Moreover, NSCs transplantation has
consistently demonstrated to promote functional motor recovery in SCI animal models. For instance,
Kadoya et al. (2016) demonstrated that transplanted rats have an improved motor function,
by performing the staircase task, which is a supraspinal dependent test and requires a skilled
forelimb control [144]. Lu et al. (2017) also reported that even 18 months after NSCs transplantation,
cells differentiate and promote functional recovery [150]. Finally, and particularly important, the vast
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majority of the studies transplanted human-derived NSCs into animal models, which imposes the use
of immunosuppressant drugs in combination with the cells. From the immunological point of view,
several studies showed that when exogenous NSCs are combined with immunosuppressant drugs they
can successfully integrate in the rat/mouse spinal cord without immune rejection [27,166,167]. However,
data from clinical trials have shown that when the immunosuppressant therapy is over, patients
experience complications related with immune rejection of the new tissue (please see Section 2.4) [168].
For this reason, the development of iPSCs-based therapies is very important to minimize the probabilities
of immune rejection by the patient. Therefore, differentiation of NSCs from iPSCs allows to acquire a
patient-specific source of suitable cells that can differentiate into neuronal lineages with the aim to
replace and assist the damaged neurons.
Due to the complexity of the SCI pathophysiology, different approaches have been developed
combining cell-based transplantation with other target-therapies. For instance, after combining
chondroitinase ABC (ChABC) treatment with iPSC-derived NSCs mice showed improvements in the
forelimb grip strength and forelimb/hindlimb locomotion. The cells were injected after injury, but the
ChABC treatment was only administrated 7 wpi. Interestingly, the grafts showed improved survival
and differentiation potentially promoting functional synaptic connectivity [27]. With a different strategy,
Okubo et al. (2018) injected gamma-secretase inhibitor (GSI)-treated hiPSC-NS/PC into a chronic SCI
model. After injection mice showed a significant increase in axonal growth, remyelination, inhibitory
synapse formation within the host neural circuitry, and reticulospinal tract fiber formation. In fact,
previous work from the group, demonstrated that GSI treatment inhibits Notch signaling promoting
neuronal differentiation [169]. Finally, combining these favorable factors leads to motor improvements
in lesioned animals [165].
Moreover, biomaterials have also been currently applied as artificial extracellular matrix with the
aim to increase the survival of transplanted stem cells. Using a laminin-coated hydrogel with dual
porosity, iPSC-NPs were seeded and further transplanted into a rat model of chronic SCI. The cells
survived over time and promoted the growth of host axons, astrocytes, and blood vessels; however, no
locomotor recovery was observed [166].
Overall, a vast number of approaches have been employed to achieve the best outcome and a
significant regeneration of the damaged neurons after SCI, however, some challenges remain to be
overcome. Cell-based therapy is a promising strategy since it is capable to target different events,
allowing a neuroprotective environment and regenerative support in the injured spinal cord. Therefore,
regeneration of the adult spinal cord cannot be thought as a one-step process, but rather as a multiple
cascade-process overtime.
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Table 2. Preclinical studies using neural stem cells transplantation to target spinal cord injury repair.
SCI Animal Model Injury TransplantedCells Time
Additional
Treatments Outcomes REF
Transection Fischer 344 RatC57BL/6 Mice
T3
C4
Rat E14
SC-derived NPCs
Mouse E12
SC-derived cells
2 w
Cell grafts survival
Full-fill of the cavitation site
Axonal CST regeneration and functional synaptic formation
Improved forelimb function
[144]
Contusion C57BL/6 Mice T9/10 Mouse Fetal BrainNSCs 1 w
Migration from the injection site toward the injury
Locomotor improvement
Reduction in neutrophils and iNOS+/Mac-2+ cells
Downregulation of TNF-α, IL-1β, IL-6 and IL-12
[170]
Hemisection Fischer 344 Rat C5 Rat E14SC-derived NPCs 2 w 4-factor cocktail
Consistent graft survival
Neuronal differentiation
Reduction of the lesion site
[145]
Compression Wistar Rat T10
Human Fetal
Spinal Cord
SPC-01 cell line
1 w
Downregulation of TNF-α
Inhibition of p65 NF-κB
Reduction of glial scar and cavity size
Gray matter preservation
[147]
Compression C57BL/6 Mice T6 ES-dNSC 1 w
Enhancement of spared neural tissue
Differentiation into oligodendrocytes
Motor improvement
[171]
Hemisection Nude Rat C5 H9 ESC-derivedNSCs 2 w
Graft size stable over time
Differentiation into mature neurons and glia
Long axonal regrowth
Glial migration to host white matter
[150]
Contusion NOD-scid Mice T9 hCNS-derivedNSCs 0
Astroglial differentiation of donor cells in the lesion site
No locomotor recovery [138]
Transection Nude Rat C4 hPSC-derivedSpinal Cord NSCs 2 w
NSCs committed to a spinal cord phenotype
Differentiation into excitatory neurons
Regeneration of the CST
Host-to-graft synaptic connectivity
[151]
Compression
WT Mouse
C3Fe.SWV-Mbpshi/J
Mice
T6 iPS-derived NSCs 1 w
Integration within the lesion site
Differentiation to oligodendrocytes
wt-iPS-dNSCs promote remyelination and axonal function
Motor Improvements
[53]
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Table 2. Cont.
SCI Animal Model Injury TransplantedCells Time
Additional
Treatments Outcomes REF
Compression Wistar Rat T8 iPS-derived NPs 1 w
Intraspinal implantation promote:
> gray and white matter sparing
> axonal sprouting
> astrogliosis reduction
Moderate functional recovery
[152]
Compression Wistar Rat T8/T9 hiPSC-derivedNPs 1 w
Cell survival and tissue preservation
Differentiation into the three germ layers
Motor improvement
Increased expression of NFs
Neuronal regeneration
[153]
Contusion C57BL/6 Mice T10 iPSC-derivedNPCs 1 w
Neuronal lineage differentiation
No tumor formation
No locomotor recovery
[167]
Contusion Long-Evanshooded Rat T10
Human Fetal Brain
NSCs 4 w
Trophic effect in the CSF
Motor improvement [140]
Contusion C57BL/6 Mice T9 Mouse StriatalNS/PCs
7–10
d Treadmill Training
Differentiation into neurons, oligodendrocytes, and astrocytes
Electrophysiologic recovery
Locomotor improvements
[141]
Contusion Rat T10 Rat Spinal CordNSCs
13
w
Ch combined with
NFs
60% of survival
< 40% of the lesion site covered
Improvement in bladder function
[172]
Hemisection Tree Shrew T10 Shrew Fetal NSCs 9 d
Self-renewal potential
Differentiation into neurons and astrocytes
Production of NFs (CNTF, TGF-β1, GDNF, NGF, BDNF and IGF)
[142]
Contusion Wistar Rat C6/C7 Rat Fetal BrainNSCs 10 d
Long-term survival
Differentiation along the oligodendroglial lineage
Reduction in M1 macrophages
Lower density of iNOS
Functional recovery
Reduction in apoptosis
[143]
Contusion Sprague–DawleyRat T12
mESC-derived
NPCs 3 w
In vitro differentiation into a spinal GABAergic phenotype
Attenuation of chronic neuropathic pain [146]
Hemisection Nude Rat C5 Human H9ESC-derived NSCs 2 w
No cellular migration
Improvement in skilled forelimb motor function [149]
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Table 2. Cont.
SCI Animal Model Injury TransplantedCells Time
Additional
Treatments Outcomes REF
Contusion C57BL/6 Mice C6/C7 iPS-derived NSCs 8 w Intrathecal ChABC
Cell survival
Remyelination and synaptic formation
Behavioral recovery of the forelimb grip strength and locomotion
[27]
Contusion NOD-SCID Mice T10 hiPSC-derivedNS/PCs 6 w GSI
Axonal regrowth and remyelination
Reticulo-spinal tract fiber formation
Motor functional recovery
[165]
Compression Wistar Rat T8/T8 hiPSC-derivedNS/PCs 5 w
Laminin-coated
pHEMA-MOETACl
hydrogel
Survival and integration within the lesion spinal cord
Reduction in cavity depth and axonal growth
Increased number of astrocytes, blood vessels, and TH+ fibers
No locomotor recovery
[166]
Abbreviations: w weeks; d days; wt wild-type; ChABC chondroitinase ABC; NTFs neurotrophic factors; GSI gamma-secretase inhibitor; CST corticospinal tract; BDNF brain-derived
neurotrophic Factor; bFGF basic-fibroblastic growth Factor; VEGF vascular endothelial growth factor; NSC neural stem cell; NPC neural progenitor cell; iPSC-derived NSC induced
pluripotent stem cell-derived NSCs; mESC-derived NPCs mouse embryonic stem cell–derived NPCs; hiPSC-derived NS/PCs human induced pluripotent stem cell-derived NS/PCs;
ES-dNSC embryonic stem-definitive NSCs; hCNS-derived NSCs human central nervous system-derived NSCs.
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2.4. SCI Clinical Trials Based on NSCs
Translational medicine has been one of the biggest challenges in science and medicine. Interestingly,
the European Society for Translational Medicine (EUSTM) defined it as an interdisciplinary branch of
the biomedical field supported by three main pillars: benchside, bedside, and community [173]. Promising
studies have been developed concerning NSCs transplantation to different SCI models, inciting
now an important and necessary transition from the benchside-to-bedside. Although the encouraging
results reported in preclinical studies, translation into the clinical set is still very challenging [174],
being the main limitations: anatomical differences between experimental animal models and human
SCI [175]; inconsistency observed in the therapeutic efficacy; variability in NSCs generation; number
of transplanted cells; logistics to obtain donor cells that can be reliable and safely stored for clinical
use; ethical concerns; sample size and subject selection criteria; absence of standardization in the
post-assessment tests; and extensive costs of running clinical trials.
To date, a low number of clinical trials have been conducted for SCI patients using NSCs,
nevertheless, some have already been concluded and others are still ongoing (Table 3).
The first clinical trial using NSCs was approved in 2005 by the Yonsei University Health System,
Severance Hospital, Republic of Korea (Clinical Research Information Service (CRIS), Registration
Number: KCT0000879). The phase I/ II clinical trial was based on the transplantation of NSC-derived
from brain fetal tissue. Human NSCs neurospheres between P10–P20 were carefully selected and
prepared for transplantation into 19 patients which were subdivided into four groups according to
the time window between the injury onset and transplantation: acute (<1 week), early subacute
(1–8 weeks), late subacute (9 weeks–6 months), and chronic (>6 months). A control group was
also addressed to the clinical trial of 15 patients with traumatic cervical SCI. After 1 year, the study
concluded that hNSCs transplantation is safe and well-tolerable by patients since no adverse evidence
was observed. The patients did not exhibit evidence of cord damage, syrinx or tumor formation, neither
neurological deterioration nor exacerbating neuropathic pain and spasticity. Regarding neurological
outcomes, based on the American Spinal Injury Association Impairment Scale (AIS) grade, 5 out of 19
transplanted patients showed beneficial alterations, including recovery at the motor level and increased
motor scores, whereas only 1 patient in the control group showed improvement [176].
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Table 3. Spinal Cord Injury Clinical Trials using NSC-based therapies.
Start Year Sponsor Country NTC/I.D. ClinicalPhase
SCI
Cohort Cell-Type Cell Source Safety Improvements Others REF
2005
Yonsei University
Health System,
Severance Hospital
KR KCT0000879 Phase I/II Cervical hNSPCs Fetal brain Safe andwell-tolerable
Partial
sensorimotor
function
No cord damage, syrinx or
tumor formation
No neurological deterioration,
and exacerbating neuropathic
pain or spasticity
Incomplete sensory recovery
[176]
2011 StemCells, Inc. CANCH NCT01321333 Phase I/II T2-T11 HuCNS-SCs Fetal brain
Safe and
well-tolerable
Segmental
sensory
Decline in sensory gains lost
after withdrawal of the
immunosuppressive
[168]
2012 StemCells, Inc. CH NCT01725880 Phase I/II T2-T11 HuCNS-SCs Fetal brain
Study terminated
based on a business
decision
[177]
2013 Neuralstem Inc. US NCT01772810 Phase I T2-T12 NSI-566cell line
Fetal spinal cord
(cervical and
upper thoracic
regions)
Safe and no side
effects 18–27 months
after cell delivery
Low sample size
(n = 4)
Still Recruiting
[178]
2014 StemCells, Inc. USCAN NCT02163876 Phase I/II C5-C7 HuCNS-SCs Fetal brain
Slight motor
strength but the
study was
terminated based on
a business decision
[179]
2017 University of Zurich CH NCT03069404 Phase I/II T2-T11 HuCNS-SCs Fetal brain No data [180]
2014
Federal Research
Clinical Center of
Federal Medical &
Biological Agency
RU NCT02326662 Phase I/II
Neck,
thoracic or
lumbar
drNSCs BMCs Safe with anycomplications
Neurologic
state [181]
2016 Chinese Academy ofSciences CN NCT02688049 Phase I/II C5-T12 NSCs
No data
Still recruiting [182]
2010 AsteriasBiotherapeutics US NCT01217008 Phase I
Neurologically
Complete,
Subacute
GRNOPC1 hESCs
The study was
terminated based on
financial issues
[183]
2015 AsteriasBiotherapeutics US NCT02302157 Phase I/II C4-C7 AST-OPC1 hESCs
Favorable safety
profile
Some hand
functions [184]
Abbreviations: T thoracic; US United States; CAN Canada; CH Switzerland; CN China; RU Russian Federation; KR Republic of Korea; NSCs neural stem cells; hESCs human embryonic
stem cells; BMCs bone marrow cells; HuCNS-SCs human central nervous system stem cells; NSI-566 cell line human spinal-cord-derived NSC; drNSC directly reprogrammed autologous
NSCs; AST-OPC1 AST-oligodendrocyte progenitor cells; GRNOPC1 human embryonic stem cell-derived OPCs.
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Neuralstem Inc. (Germantown, MD, USA) began a phase I safety trial (clinicaltrials.gov identifier:
NCT01772810) at the University of California San Diego to intramedullary injected an FDA-approved
NSI-566RSC cell line into thoracic (T2-T12) SCI subjects. NSI-566RSC line is derived from the cervical
and upper thoracic regions of the spinal cord from an 8 gestational weeks human fetus. The first report
was published by Curtis et al. (2018) showing that NSI-566 grafts are safe and have no detectable
side effects after 18–27 months of cell transplantation [178]. However, the small sample size (n = 4)
is a major drawback in the assessment of this one-open-arm study. Nevertheless, future studies are
needed and justified due to the positive results regarding the safety and tolerability of NSI-566RSC
cells in subjects.
As mentioned before, Asterias Biotherapeutics Inc. (Fremont, CA, USA) has also begun a safety
trial in the implementation of human ESC-derived oligodendrocyte progenitors (GRNOPC1 cells) [78]
in patients with neurologically complete subacute SCI (clinicaltrials.gov identifier no. NCT01217008).
Although some financial problems delay the initial study, a second clinical trial was initiated as a phase
I/IIa dose-escalation study using the same embryonic-derived OPCs (NCT02302157). Preliminary
results suggest improvements in motor function, but further data still needed [80].
In 2014, a different clinical trial was also initiated to evaluate the safety and the potential of
directly reprogrammed autologous NSCs (drNSCs) in subacute and chronic SCI subjects (Federal
Research Clinical Center of Federal Medical & Biological Agency, Russia, NCT02326662). Directly
reprogrammed NSCs were generated from patients’ bone marrow cells (BMCs) using a patented
reprogramming xeno-free cocktail. The grafts were directly injected into the white and grey matter of
the spinal cord adjacent to the lesion after the implantation of a regeneration matrix (RMx). Although
the sample size presented by the study is extremely limited (n = 5), after 6–9 months of follow-up
there was no complications or side effects associated with the intervention, and all patients showed
improvements in the neurologic state.
Many different reports have already described the benefits of research cell lines transplantation
into rodent models of thoracic contusion SCI [185–188]. Concomitantly to these results, Stemcells,
Inc. led a phase II clinical trial in thoracic SCI patients using the HuCNS-SCs cell line (NCT02163876).
The main aim was to escalate the dose safety and efficacy, 4 months after injury, of intramedullary
injections rostral and caudally to C5-C7 injury. An optimistic press release of interim 6-month data
(November 18, 2015) reported improvements in motor strength in 4 out of 5 subjects. Using the same
HuCNS-SCs, Anderson et al. (2017) inject them in an in vivo preclinical study to validate locomotor
and sensory recovery, cell engraftment, migration, and neural lineage fate of cells [48]. Yet, no evidence
of HuCNS-SCs efficacy was observed raising awareness for the necessity of validation of cell lines
and/or in cell manufacture/processing, to diminish possible variations and ensure consistency along
preclinical studies to clinical trials. Nevertheless, after one-year post-transplantation, no evidence of
additional spinal cord damage, new lesions, or syrinx formation was observed in patients. An efficacy
threshold was previously set by the sponsor to further support the study and by citing a lack of
significant improvements and trend for improvements over time, StemCells Inc. actually terminated
the study [189].
In 2011, a new phase I/II clinical trial (NCT01321333) was sponsored by Stem Cells Inc.
and managed at the University Hospital Balgrist (Zurich, Switzerland). Based on previous preclinical
studies, the main focus was to assess the safety and preliminary efficacy of human CNS stem cells
(HuCNS-SC) transplantation. The trial included 12 thoracic (T2-T11) SCI patients who sustained
an injury within 3–12 months prior to cell transplantation. At the injection time, patients received
approximately a total of 20 million cells directly into the spinal cord, 2 injections rostral and 2 caudally
to the injury site. After 12-months o, HuCNS-SC showed to be safe and feasible concerning the
surgery and the cellular transplant. More interestingly, 7 out of the 12 patients experienced sensory
improvements after neurological stability [178].
Following these positive results, a second clinical trial was approved (NCT01725880) to perform a
long-term follow-up of the transplanted HuCNS-SC subjects. However, some obstacles appeared that
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should be carefully considered. After 9 months of immunosuppression, the agents were removed and
the sensory gains were lost. It seems that the immune system was rejecting the transplanted cells which
culminate with the ceasing of the long-term follow up. Although the result observed in SCI patients
was not expected, this warned the field for a real problem in transplant non-patient cells that might be
challenging the host immune system. Consequently, the cell source used for clinical cell transplantation
must be rethought being NSCs-derived from iPSCs one of the most attractive alternatives.
Okano’s team in Japan is proposing the launch of the human clinical study using allogenic
iPSC-derived NSCs for subacute SCI patients. The costs associated with quality testing, safety
concerns and time-consuming for autologous transplants have led the team to an increased interest
in an allogeneic alternative. Therefore, the Center for iPS Cell Research and Application (CiRA)
at Kyoto University will donate “iPSCs of human leucocyte antigen (HLA) super-donors” for cell
transplant intervention, which are clinical-grade allogenic immunologically match clones and no
adverse outcomes are expected. Thus, the conduction of this clinical trial intends firstly to address
safety and tumorigenesis issues associated with the transplantation of these clones into humans as a
future viable therapeutic intervention [190,191].
Overall, clinical trials have been showing some modest improvements to the SCI patients.
More important, these trials have not shown major safety problems, however the clinical trial perform
by University Hospital Balgrist shown that after stopping immunosuppression complications may
arise. For these reasons, autologous iPSC-derived NSCs are the most promising cell source to repair
the injured spinal cord. This section was only based on the NSCs-based, however, several different
therapeutic agents were or are being testing in clinical settings with the aim to promote SCI repair.
For more information about clinical trials in a SCI context please read the following reviews [192–195].
3. Future Perspectives
NSCs are a promising therapeutic approach for SCI repair. NSCs can differentiate and replace
the lost neural tissue as well as secrete neurotrophic factors that can protect or regenerate the tissue.
Nevertheless, further studies are necessary to confirm neurological and functional benefits, safety,
adjusting doses and administrations periods, and to select the most promising cellular sources to obtain
NSCs. Despite all the efforts and progress, the match between preclinical models and human SCI is
still poorly established but several ongoing clinical can provide an important avenue for future cell
transplantation research. It is also important to highlight that cellular transplantation alone may not be
a sufficient approach to completely treat the injured spinal cord, therefore, combinatory therapies may
be necessary for the treatment of this devastating injury.
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